March 11, 2021 -- Johnson & Johnson announced it has moved a step closer toward marketing authorization for its single-dose COVID-19 vaccine candidate in Europe.
The European Medicines Agency (EMA) issued a positive opinion to recommend conditional marketing authorization (CMA) for the company's single-dose COVID-19 vaccine candidate, developed by the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen), to prevent COVID-19 in individuals 18 years of age and older.
If granted a CMA by the European Commission, the J&J single-shot COVID-19 vaccine will be available in the European Union. Studies of the vaccine have demonstrated protection against COVID-19-related hospitalization and death in broad geographic regions, including those with emerging variants.
Copyright © 2021 scienceboard.net